Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionGotham Asset Management, LLC
ManagerJoel Greenblatt
Latest Disclosed Ownership360,136 shares
Latest Disclosed Value $ 47,444,317
Gotham Asset Management, LLC reports 113.64% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Gotham Asset Management, LLC filed a 13F-HR form disclosing ownership of 360,136 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $47,444,317 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 168,572 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 113.64% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 360,136 191,564 113.64 47,444 98.44 0.1453
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 168,572 32,218 23.63 23,909 24.90 0.0873
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 136,354 45,225 49.63 19,141 67.11 0.0833
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 91,129 60,106 193.75 11,454 233.84 0.0685
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,023 25,309 442.93 3,431 340.44 0.0286
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,714 -9,603 -62.70 780 -55.84 0.0074
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,317 -22,962 -59.99 1,765 -66.52 0.0183
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 38,279 32,975 621.70 5,270 620.79 0.0682
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,304 -234 -4.23 732 0.27 0.0110
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,538 480 9.49 730 28.12 0.0135
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,058 -355 -6.56 569 11.57 0.0118
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,413 -2,180 -28.71 510 -33.59 0.0111
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,593 -236 -3.01 769 -17.86 0.0186
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,829 2,204 39.18 935 56.62 0.0263
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,625 29 0.52 597 9.54 0.0179
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,596 -1,427 -20.32 545 -17.17 0.0175
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,023 4,465 174.55 658 201.83 0.0204
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,558 2,558 218 0.0070
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -18,712 -100.00 0 -100.00
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,712 5,870 45.71 1,799 14.81 0.0578
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,842 -6,363 -33.13 1,567 -5.72 0.0469
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,205 -10,460 -35.26 1,662 -47.88 0.0462
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 29,665 15,730 112.88 3,189 153.90 0.0586
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,935 3,431 32.66 1,256 41.60 0.0222
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,504 -8,828 -45.67 887 -47.92 0.0142
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,332 2,956 18.05 1,703 45.68 0.0249
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,376 -7,246 -30.67 1,169 -59.75 0.0182
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 23,622 16,209 218.66 2,904 298.90 0.0401
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,413 7,413 728 0.0105
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.